Last updated: March 1, 2026
What is the existing market for the drug under NDC 49884-0186?
NDC 49884-0186 refers to Vyepti (eptinezumab), used for preventive treatment of migraine in adults. It is a monoclonal antibody targeting calcitonin gene-related peptide (CGRP).
Market Size and Growth
- Estimated global migraine treatment market was valued at USD 3.5 billion in 2021.
- Expected compound annual growth rate (CAGR): approximately 7.9% from 2022 to 2030.
- The US market accounts for around 40% of total sales, driven by high prevalence and insurance coverage.
Prevalence Data
- Around 39 million Americans affected by migraine.
- US annual migraine medication expenditure exceeds USD 2 billion.
- The adoption rate of biologics like eptinezumab is increasing due to their efficacy in resistant cases.
Competitive LAMs and Portfolio
- Other CGRP inhibitors: Replens (erenumab), Ajovy (fremanezumab), Emgality (galcanezumab).
- Orally administered options: ubrogepant, rimegepant.
Who are the key competitors?
| Drug Name |
Class |
Approvals |
Market Share (2022) |
Price Range (per dose) |
| Vyepti (eptinezumab) |
Monoclonal antibody (IV) |
FDA (2020), EMA (2021) |
15-20% |
USD 385-420 (per 100 mg IV infusion) |
| Reblon (erenumab) |
Monoclonal antibody (Subq) |
FDA (2018), EMA (2018) |
25-30% |
USD 575-625 (monthly injection) |
| Ajovy (fremanezumab) |
Monoclonal antibody (Subq) |
FDA (2018), EMA (2018) |
10-15% |
USD 575-600 (monthly or quarterly) |
| Emgality (galcanezumab) |
Monoclonal antibody (Subq) |
FDA (2018), EMA (2019) |
10-15% |
USD 645 (monthly injection) |
Price Projections for NDC 49884-0186
Current Pricing
- Average per dose: USD 385-420.
- Administration: IV infusion every 3 months.
- Reimbursement landscape: Insurers cover majority of costs; patient copay varies.
Short-term Outlook (Next 2 years)
- Incremental price adjustments likely remain within a 3-5% annual range due to inflation and competitive pressures.
- Price stabilization expected as market penetration matures.
- Potential discounts for formulary inclusion may lower effective prices by 10-15%.
Medium to Long-term Outlook (3-5 years)
- Introduction of biosimilars is unlikely within this timeframe due to biologic complexity and market exclusivity.
- Pricing could decline modestly (>10%) if new entrants or improving clinical evidence drive negotiations.
- Reimbursement rates might shift favorably for oral or less costly generics if new therapies outperform biologics in certain niches.
External Factors Impacting Pricing
- Regulatory decisions: Faster approval or acceptance of biosimilars would influence prices.
- Market exclusivity: FDA exclusivity for biologics like eptinezumab lasts 12 years.
- Insurance policy changes: Increased cost-sharing or value-based pricing models could lower net prices.
- Patent landscape: Patent expiry not expected before 2030; generic biosimilars unlikely before that.
Market Dynamics and Trends
- Adoption among patients resistant to oral medications is driving growth.
- Physician preference leans toward IV biologics for refractory cases, sustaining high prices.
- Value-based contracts are being tested, linking payment to treatment outcomes, which could influence net prices.
- Developing markets show slower uptake due to reimbursement challenges and access issues.
Pricing Benchmarks
- Comparable CGRP inhibitors range USD 575-645 per dose.
- Eptinezumab's IV administration incurs higher operational costs compared to subq options, possibly justifying a higher price point.
- Payers are demanding data on clinical benefits versus cost to negotiate discounts.
Summary
| Aspect |
Details |
| Market Size |
USD 3.5 billion (2021) |
| CAGR |
7.9% (2022-2030) |
| Key Competitors |
Reblon, Ajovy, Emgality |
| Current Price Range |
USD 385-420 per infusion |
| Price Trend (Next 2 Years) |
3-5% annual increase, potential discounts |
| Longer-term Predictions |
Slight decrease; biosimilars unlikely before 2030 |
Key Takeaways
- The migraine biologics market is expanding at nearly 8% CAGR.
- NDC 49884-0186, Vyepti, prices remain stable within a high-range biologic segment.
- Competitive and regulatory landscapes could exert downward pricing pressure by 2025.
- Insurance dynamics, especially formulary placements, heavily influence effective patient costs.
- No biosimilar competition is expected soon; pricing sustainability hinges on clinical and economic position.
FAQs
1. Will prices of Vyepti decrease with increased competition?
It is unlikely within the next 2-3 years. Biosimilar development faces scientific and regulatory hurdles, delaying competition.
2. How does reimbursement impact Vyepti’s effective pricing?
Reimbursement policies and formulary negotiations significantly influence actual net prices paid by insurers, often reducing out-of-pocket costs for patients.
3. Are savings expected if biosimilars enter the market?
Yes. Biosimilars could lower prices by 15-30%, but market entry constraints might delay this effect beyond 2030.
4. Which factors could drive a price increase?
Introduction of new indications, improved clinical outcomes, or higher demand due to increasing migraine prevalence could support price stability or increases.
5. What are the prospects for new entrants?
Biologics manufacturing complexity and patent protections limit immediate competition. Market entry may occur post-2030, contingent on innovation and regulatory approvals.
References:
- MarketsandMarkets. (2022). Migraine Medications Market.
- IQVIA. (2022). Pharmaceuticals Data & Pricing Trends.
- FDA. (2020). Vyepti (eptinezumab) approval documentation.
- Statista. (2022). Migraine Treatment Market Revenue.
- AAN. (2022). Migraine Clinical Practice Guidelines.
